Infinity Conducting Clinical Trial in Patients With Pancreatic Cancer in Dallas
15. November 2010 09:02 ET
|
Infinity Pharmaceuticals, Inc.
Ongoing Clinical Trial Evaluating a New Approach for Pancreatic Cancer, One of the Most Difficult to Treat Cancers
Spotlight on Pancreatic Cancer Awareness Month in November
DALLAS, Nov. 15,...
Infinity Pharmaceuticals to Present at Lazard Healthcare Conference
10. November 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday,...
Infinity Provides Company Update and Reports Third Quarter 2010 Financial Results
09. November 2010 16:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 9, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today highlighted its recent business and clinical progress, and announced third quarter 2010 financial...
Infinity Augments Executive Leadership Team, Appointing New Chief Medical Officer and New Vice President, Product Development and Medical Affairs
08. November 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 8, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced two key appointments to its executive leadership team. The company named Pedro...
Infinity Awarded Approximately $750,000 in Grants for Qualifying Therapeutic Development Projects
04. November 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 4, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has been awarded three grants totaling approximately $750,000 under the U.S....
Infinity Announces That Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide
26. Oktober 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
Encouraging Topline Data From Phase 1 Study of IPI-940 Reported
Decision Demonstrates Strength of Alliance and Underscores Complementary Capabilities of the Partners
CAMBRIDGE, Mass., Oct. 26,...
Infinity Announces the Date of Its Third Quarter 2010 Financial Results Conference Call and Webcast
25. Oktober 2010 08:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 25, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will announce its third quarter 2010 financial results on Tuesday, November 9, 2010 after the financial...
Results Showing Activity of IPI-504 in Patients With Non-Small Cell Lung Cancer Published in Journal of Clinical Oncology
14. Oktober 2010 08:30 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 14, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announced that results from its Phase 2 study of IPI-504, a novel IV-administered Hsp90 chaperone...
Infinity Announces Promising Phase 1 Data of IPI-926 in Patients With Advanced or Metastatic Solid Tumors
10. Oktober 2010 06:45 ET
|
Infinity Pharmaceuticals, Inc.
MILAN, Italy, Oct. 10, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced promising preliminary results from a Phase 1 study of IPI-926, its novel, oral small...
Infinity Pharmaceuticals to Present Phase 1 Clinical Data of IPI-926 at ESMO Congress
22. September 2010 08:00 ET
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Sept. 22, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that Phase 1 data of its novel Hedgehog pathway inhibitor, IPI-926, will be presented...